Tasquinimod

Published

dm+d

Unassigned

New Medicines

Prostate cancer, hormone refractory, pre-chemotherapy

Information

New molecular entity
Ipsen
Active Biotech

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Apr 15: Development in prostate cancer discontinued [1].

Category

Immunomodulator
The age-standardised incidence of prostate cancer in the UK in 2008 was 97.9 per 100,000 population. It was estimated that the lifetime risk of being diagnosed with prostate cancer in 2008 was 1 in 9 for men in the UK. [3]
Prostate cancer, hormone refractory, pre-chemotherapy
Oral

Evidence based evaluations